Marshall Wace, LLP Keros Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

A detailed history of Marshall Wace, LLP transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 272,971 shares of KROS stock, worth $12.5 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

272,971

Previous 49,472 451.77%

Holding current value

$12.5 Million

Previous $1.97 Million 818.66%

% of portfolio

0.03%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $9.22 Million - $15.8 Million	223,499 Added 451.77%	272,971 $18.1 Million
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $1.34 Million - $2.03 Million	49,472 New	49,472 $1.97 Million
Q2 2023 Aug 14, 2023	SELL	$37.26 - $51.01 $2.01 Million - $2.75 Million	-53,870 Reduced 46.23%	62,650 $2.52 Million
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $4.56 Million - $6.53 Million	110,120 Added 1720.63%	116,520 $4.98 Million
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $252,480 - $331,328	6,400 New	6,400 $307,000

Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $1.18 Million - $3.05 Million	45,466 Added 608.81%	52,934 $1.46 Million
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $73,330 - $103,345	1,741 Added 30.4%	7,468 $406,000
Q4 2021 Feb 14, 2022	SELL	$36.95 - $62.89 $1.62 Million - $2.76 Million	-43,909 Reduced 88.46%	5,727 $335,000
Q3 2021 Nov 15, 2021	BUY	$29.27 - $43.71 $1.1 Million - $1.64 Million	37,581 Added 311.75%	49,636 $1.96 Million
Q2 2021 Aug 13, 2021	BUY	$42.4 - $70.11 $261,947 - $433,139	6,178 Added 105.12%	12,055 $512,000
Q1 2021 May 17, 2021	SELL	$54.0 - $75.28 $627,210 - $874,377	-11,615 Reduced 66.4%	5,877 $362,000
Q4 2020 Feb 16, 2021	BUY	$36.0 - $82.74 $629,712 - $1.45 Million	17,492 New	17,492 $1.23 Million

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Keros Therapeutics, Inc. Transaction History